MyoKardia, Inc. (MYOK)

Last Price:  

Company Description

MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $33.56M
Net Income (Most Recent Fiscal Year) $-276.21M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 12.73
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -51.01%
Return on Assets (Trailing 12 Months) -45.43%
Current Ratio (Most Recent Fiscal Quarter) 7.83
Quick Ratio (Most Recent Fiscal Quarter) 7.83
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $8.79
Earnings per Share (Most Recent Fiscal Quarter) $-1.50
Earnings per Share (Most Recent Fiscal Year) $-4.38
Diluted Earnings per Share (Trailing 12 Months) $-6.67
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 46.68M
Free Float 44.67M
Market Capitalization $4.45B
Average Volume (Last 20 Days) 0.48M
Beta (Past 60 Months) 2.31
Percentage Held By Insiders (Latest Annual Proxy Report) 4.30%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%